Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy

A randomized trial

Hideto Kameda, Yukitaka Ueki, Kazuyoshi Saito, Shouhei Nagaoka, Toshihiko Hidaka, Tatsuya Atsumi, Michishi Tsukano, Tsuyoshi Kasama, Shunichi Shiozawa, Yoshiya Tanaka, Tsutomu Takeuchi

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The superiority of the combination therapy of methotrexate (MTX) and anti-tumor necrosis factor (TNF) biological agents over anti-TNF monotherapy in MTX-naïve patients with rheumatoid arthritis (RA) has been demonstrated. We investigated the efficacy and safety of continuation versus discontinuation of MTX at the commencement of etanercept (ETN) in patients with active RA despite MTX therapy. In total, 151 patients with active RA despite treatment with MTX were randomized to either ETN 25 mg twice a week and MTX 6-8 mg/week (the E + M group) or ETN alone (the E group). Co-primary endpoints included the European League Against Rheumatism (EULAR) good response rate and the American College of Rheumatology (ACR) 50 response rate at week 24. Demographic and clinical features between groups at baseline were similar. The EULAR good response rates were significantly higher in the E + M group (52%) than in the E group (33%) at week 24 (p = 0.0001). Although the ACR50 response rate, one of the co-primary endpoints, and the ACR70 response rate at week 24 were not significantly greater in the E + M group (64 and 38%, respectively) than in the E group (48 and 26%, respectively), the ACR20 response rate was significantly greater in the E + M group (90%) than in the E group (64%; p = 0.0002). Safety profiles were similar for the groups. Thus, MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX.

Original languageEnglish
Pages (from-to)531-538
Number of pages8
JournalModern Rheumatology
Volume20
Issue number6
DOIs
Publication statusPublished - 2010 Dec

Fingerprint

Methotrexate
Rheumatoid Arthritis
Therapeutics
Tumor Necrosis Factor-alpha
Safety
Etanercept
Biological Factors
Rheumatic Diseases
Demography

Keywords

  • ACR response
  • Anti-TNF
  • Biological agent
  • Combination therapy
  • EULAR response

ASJC Scopus subject areas

  • Rheumatology

Cite this

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy : A randomized trial. / Kameda, Hideto; Ueki, Yukitaka; Saito, Kazuyoshi; Nagaoka, Shouhei; Hidaka, Toshihiko; Atsumi, Tatsuya; Tsukano, Michishi; Kasama, Tsuyoshi; Shiozawa, Shunichi; Tanaka, Yoshiya; Takeuchi, Tsutomu.

In: Modern Rheumatology, Vol. 20, No. 6, 12.2010, p. 531-538.

Research output: Contribution to journalArticle

Kameda, Hideto ; Ueki, Yukitaka ; Saito, Kazuyoshi ; Nagaoka, Shouhei ; Hidaka, Toshihiko ; Atsumi, Tatsuya ; Tsukano, Michishi ; Kasama, Tsuyoshi ; Shiozawa, Shunichi ; Tanaka, Yoshiya ; Takeuchi, Tsutomu. / Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy : A randomized trial. In: Modern Rheumatology. 2010 ; Vol. 20, No. 6. pp. 531-538.
@article{6de7eeadfd054f9fb58988ee1b5749e0,
title = "Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial",
abstract = "The superiority of the combination therapy of methotrexate (MTX) and anti-tumor necrosis factor (TNF) biological agents over anti-TNF monotherapy in MTX-na{\"i}ve patients with rheumatoid arthritis (RA) has been demonstrated. We investigated the efficacy and safety of continuation versus discontinuation of MTX at the commencement of etanercept (ETN) in patients with active RA despite MTX therapy. In total, 151 patients with active RA despite treatment with MTX were randomized to either ETN 25 mg twice a week and MTX 6-8 mg/week (the E + M group) or ETN alone (the E group). Co-primary endpoints included the European League Against Rheumatism (EULAR) good response rate and the American College of Rheumatology (ACR) 50 response rate at week 24. Demographic and clinical features between groups at baseline were similar. The EULAR good response rates were significantly higher in the E + M group (52{\%}) than in the E group (33{\%}) at week 24 (p = 0.0001). Although the ACR50 response rate, one of the co-primary endpoints, and the ACR70 response rate at week 24 were not significantly greater in the E + M group (64 and 38{\%}, respectively) than in the E group (48 and 26{\%}, respectively), the ACR20 response rate was significantly greater in the E + M group (90{\%}) than in the E group (64{\%}; p = 0.0002). Safety profiles were similar for the groups. Thus, MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX.",
keywords = "ACR response, Anti-TNF, Biological agent, Combination therapy, EULAR response",
author = "Hideto Kameda and Yukitaka Ueki and Kazuyoshi Saito and Shouhei Nagaoka and Toshihiko Hidaka and Tatsuya Atsumi and Michishi Tsukano and Tsuyoshi Kasama and Shunichi Shiozawa and Yoshiya Tanaka and Tsutomu Takeuchi",
year = "2010",
month = "12",
doi = "10.1007/s10165-010-0324-4",
language = "English",
volume = "20",
pages = "531--538",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy

T2 - A randomized trial

AU - Kameda, Hideto

AU - Ueki, Yukitaka

AU - Saito, Kazuyoshi

AU - Nagaoka, Shouhei

AU - Hidaka, Toshihiko

AU - Atsumi, Tatsuya

AU - Tsukano, Michishi

AU - Kasama, Tsuyoshi

AU - Shiozawa, Shunichi

AU - Tanaka, Yoshiya

AU - Takeuchi, Tsutomu

PY - 2010/12

Y1 - 2010/12

N2 - The superiority of the combination therapy of methotrexate (MTX) and anti-tumor necrosis factor (TNF) biological agents over anti-TNF monotherapy in MTX-naïve patients with rheumatoid arthritis (RA) has been demonstrated. We investigated the efficacy and safety of continuation versus discontinuation of MTX at the commencement of etanercept (ETN) in patients with active RA despite MTX therapy. In total, 151 patients with active RA despite treatment with MTX were randomized to either ETN 25 mg twice a week and MTX 6-8 mg/week (the E + M group) or ETN alone (the E group). Co-primary endpoints included the European League Against Rheumatism (EULAR) good response rate and the American College of Rheumatology (ACR) 50 response rate at week 24. Demographic and clinical features between groups at baseline were similar. The EULAR good response rates were significantly higher in the E + M group (52%) than in the E group (33%) at week 24 (p = 0.0001). Although the ACR50 response rate, one of the co-primary endpoints, and the ACR70 response rate at week 24 were not significantly greater in the E + M group (64 and 38%, respectively) than in the E group (48 and 26%, respectively), the ACR20 response rate was significantly greater in the E + M group (90%) than in the E group (64%; p = 0.0002). Safety profiles were similar for the groups. Thus, MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX.

AB - The superiority of the combination therapy of methotrexate (MTX) and anti-tumor necrosis factor (TNF) biological agents over anti-TNF monotherapy in MTX-naïve patients with rheumatoid arthritis (RA) has been demonstrated. We investigated the efficacy and safety of continuation versus discontinuation of MTX at the commencement of etanercept (ETN) in patients with active RA despite MTX therapy. In total, 151 patients with active RA despite treatment with MTX were randomized to either ETN 25 mg twice a week and MTX 6-8 mg/week (the E + M group) or ETN alone (the E group). Co-primary endpoints included the European League Against Rheumatism (EULAR) good response rate and the American College of Rheumatology (ACR) 50 response rate at week 24. Demographic and clinical features between groups at baseline were similar. The EULAR good response rates were significantly higher in the E + M group (52%) than in the E group (33%) at week 24 (p = 0.0001). Although the ACR50 response rate, one of the co-primary endpoints, and the ACR70 response rate at week 24 were not significantly greater in the E + M group (64 and 38%, respectively) than in the E group (48 and 26%, respectively), the ACR20 response rate was significantly greater in the E + M group (90%) than in the E group (64%; p = 0.0002). Safety profiles were similar for the groups. Thus, MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX.

KW - ACR response

KW - Anti-TNF

KW - Biological agent

KW - Combination therapy

KW - EULAR response

UR - http://www.scopus.com/inward/record.url?scp=78049495342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049495342&partnerID=8YFLogxK

U2 - 10.1007/s10165-010-0324-4

DO - 10.1007/s10165-010-0324-4

M3 - Article

VL - 20

SP - 531

EP - 538

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -